Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplantation: New Risk Factors and New Therapeutic...

Area of Science:

• Medical Mycology
• Hematology
• Infectious Diseases

Background:

• Invasive fungal diseases (IFD) are a major cause of mortality (30-80%) in patients undergoing immunosuppressive therapies, particularly allogeneic hematopoietic cell transplantation (alloHCT).
• Changes in GVHD prophylaxis, increased transplant survivorship, expanded access to transplantation, and use of haploidentical donors are altering the epidemiology of IFD post-alloHCT.
• Climate change is expanding the geographic range of endemic fungal infections, necessitating broader clinical awareness beyond traditional risk groups.

Purpose of the Study:

• To review the evolving landscape of IFD in patients undergoing alloHCT.
• To discuss emerging diagnostic tools and novel antifungal treatment options.
• To address the increasing challenge of antifungal resistance.

Main Methods:

• Literature review focusing on recent advancements in IFD management.
• Analysis of trends in IFD incidence, risk factors, and treatment outcomes.
• Synthesis of data on new antifungal agents and resistance patterns.

Main Results:

• The field of IFD post-alloHCT is dynamic, influenced by evolving transplant practices and expanding endemic fungal infections.
• Rising rates of antifungal resistance to azoles are observed, alongside an increase in resistant mold infections in patients receiving prophylaxis.
• New diagnostics and antifungal therapies are becoming available, offering potential improvements in IFD management.

Conclusions:

• Clinicians require heightened awareness of IFD due to changing risk profiles and geographic spread.
• The emergence of antifungal resistance necessitates careful stewardship and exploration of novel therapeutic strategies.
• Continued research and investment in surveillance, diagnostics, and treatments are critical for combating IFD in alloHCT recipients.